Longevity & AgingArtículo de investigaciónDe pago

Wearables Track Early Alzheimer's Widely, but Few Studies Test Diagnosis or Prognosis

A scoping review of 109 studies maps wearable digital biomarkers in early Alzheimer's. Few tested diagnosis (16%) or prognosis (3%).

sábado, 21 de noviembre de 2026 0 visualizaciones
Publicado en J Neurol Sci
Older adult wearing a smartwatch walking outdoors, with faint translucent gait, speech and sleep data graphs overlaid in the air

Resumen

Researchers mapped the literature on digital biomarkers from wearable or portable devices in early Alzheimer's disease, meaning mild cognitive impairment (MCI) due to AD or mild dementia. Searching three databases and screening 8,893 records, they included 109 studies covering about 3,019 people with MCI and 1,942 with mild AD (mean age 73). The most studied signals were rest/activity patterns (39%), speech (17%) and gait (14%), and most studies looked at only one domain. Only 16% reported outcomes related to diagnosis and just 3% to prognosis. This is a scoping review: it charts what has been studied and does not pool results or judge how accurate any biomarker is. The main message is that the field is growing but has a clear gap before these tools can be used clinically.

0:00--:--

Resumen detallado

Early detection and monitoring of Alzheimer's disease is a major goal, and wearable or portable devices could offer low-burden, continuous measurement. Before such tools reach clinics, it helps to know what has actually been tested.

This scoping review from the Danish Dementia Research Centre searched MEDLINE, Web of Science and EMBASE. Two reviewers independently screened and extracted data. After deduplicating and screening 8,893 records, 109 studies were included. They covered about 3,019 people with MCI due to AD and 1,942 with mild AD, around 54-55% female with a weighted mean age of 73.

The studies used a wide range of wearable or portable technologies. The most common biomarker domains were rest/activity (39% of studies), speech (17%) and gait (14%). Most studies examined a single domain. Only 16% reported outcomes tied to diagnosis and 3% to prognosis.

The implication is that many digital signals have been measured in early AD, but few studies have tested whether they can identify disease or predict its course. That is the step needed to move from development to clinical use. The authors suggest the map can guide future research, for example toward multi-domain studies and diagnostic and prognostic validation.

Caveats: the abstract does not report effect sizes, accuracy figures or study quality. A scoping review describes the landscape and does not show that any biomarker works. These findings concern research coverage, not clinical performance, and only the abstract was available for this summary.

Hallazgos clave

  • Scoping review included 109 studies from 8,893 screened records across MEDLINE, Web of Science and EMBASE.
  • Populations totaled about 3,019 people with MCI due to AD and 1,942 with mild AD, mean age 73.
  • Most studied biomarker domains were rest/activity (39%), speech (17%) and gait (14%); most studies covered one domain.
  • Only 16% of studies reported diagnostic outcomes and 3% prognostic outcomes, a major knowledge gap.
  • The review maps research activity; it does not establish accuracy or clinical usefulness of any digital biomarker.

Metodología

Scoping review searching MEDLINE, Web of Science and EMBASE, with independent review and data extraction by two team members. Included original studies of portable or wearable digital health technologies measuring digital biomarkers in early AD (MCI or mild dementia). Data were charted in tabular and graphical form without pooling results.

Limitaciones del estudio

Based on the abstract only, so study quality, device types, effect sizes and accuracy are not available. Scoping reviews do not appraise bias or synthesize performance, and the included studies are likely heterogeneous and mostly single-domain. Findings describe research coverage, not whether the biomarkers work.

¿Te ha gustado este resumen?

Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.

Introduce tu correo electrónico para suscribirte: